
The U.S. Food and Drug Administration today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds). Infilbray crosses the blood-brain barrier to reduce the accumulation of harmful substances in the body and brain.
“For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms,” said Acting FDA Commissioner Kyle Diamantas, J.D. “This approval reflects the FDA’s commitment to advancing therapeutic options for patients with rare diseases and brings an important new treatment to patients and the healthcare providers who care for them.”
GD3 is a rare, inherited condition in which the body cannot properly break down fatty substances, called glucosphingolipids, due to a deficient or malfunctioning enzyme. As these substances accumulate in organs, tissues, and the brain, patients experience a wide range of serious health problems over time. Unlike type 1 Gaucher disease, GD3 also affects the brain and nervous system, causing difficulties with balance, coordination, speech, memory, and thinking — symptoms that can worsen progressively and significantly impact quality of life. Infilbray works as a glucosylceramide synthase inhibitor, reducing the buildup of harmful substances throughout the body and, critically, within the brain.
|